Prospective Validation of the STOPSHOCK Score - Artificial Intelligence Based Predictive Scoring System to Identify the Risk of Developing Cardiogenic Shock (CS) in Patients Suffering From Acute Coronary Syndrome (ACS)
Launched by PREMEDIX ACADEMY · Jul 24, 2025
Trial Information
Current as of August 20, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Cardiogenic shock is a serious life-threatening condition affecting almost 10% of patients suffering from acute coronary syndrome (ACS). When untreated, it can rapidly progress to collapse of circulation and sudden death. Despite recent improvements in diagnostic and treatment options, mortality remains incredibly high, reaching nearly 50%. Currently available mechanical circulatory support devices can replace the function of the heart and/or lungs, thereby essentially eliminating the primary cause. However, cardiogenic shock is not only an isolated decrease in cardiac function but a rapidl...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients aged \>18 years.
- • Admitted for acute coronary syndrome in CCU
- Exclusion Criteria:
- • Patients aged \< 18 years.
- • Patients in CSWG-SCAI C, D or E CS the before the admission to CCU.
About Premedix Academy
Premedix Academy is a pioneering clinical trial sponsor dedicated to advancing medical research and improving patient outcomes through innovative study designs and robust methodologies. With a focus on education and training for healthcare professionals, Premedix Academy leverages its expertise to facilitate the development of cutting-edge therapies across various therapeutic areas. The organization emphasizes ethical practices, patient safety, and regulatory compliance, ensuring that all trials are conducted to the highest standards. By fostering collaboration among stakeholders, including researchers, clinicians, and patients, Premedix Academy aims to contribute significantly to the advancement of medical science and the enhancement of healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bratislava, , Slovakia
Patients applied
Trial Officials
Allan Böhm, MD, PhD, MSc, MBA, FESC, FJCS
Principal Investigator
Premedix Academy
Branislav Bezák, MD, PhD
Study Director
Premedix Academy
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported